Psychopharmacological interventions for ADHD Dr. Charles Pemberton, Ed.D, LPCC Manbeena Sekhon, Doctoral Student.

Slides:



Advertisements
Similar presentations
ADD Update Kristi Maroni, MD Lance Feldman, MD, MBA, BSN.
Advertisements

Sources: NIMH Mental Health: A Report of the Surgeon General Copyright © Notice: The materials are copyrighted © and trademarked ™ as the property of The.
All That Wiggles Is Not ADHD History, Assessment, and Diagnosis of ADHD Jodi A. Polaha, Ph.D. Assistant Professor, Pediatrics Munroe-Meyer Institute, UNMC.
Carolyn R. Fallahi, Ph. D. Attention Deficit Hyperactivity Disorder.
Attention-Deficit /Hyperactivity Disorder (ADHD)
Attention-Deficit/ Hyper Activity Disorder ( ADHD) By: Bianca Jimenez Period:5.
ADHD & ADD Understanding the Criteria for Attention Deficit Hyperactivity Disorder Adapted from American Psychiatric Association. (1994). Diagnostic and.
A TTENTION DEFICIT DISORDERS With/Without hyperactivity Dr. Kersi Chavda.
ADHD, Executive Functions and PKU Kevin M. Antshel, Ph.D. Associate Professor of Psychiatry / Licensed Psychologist State University of New York – Upstate.
ADHD in the Classroom: Diagnosis and Treatment Dr. Charles Pemberton, Ed.D, LPCC.
ADHD By Elizabeth Mihalick. What is ADHD?  Attention deficit hyperactivity disorder (ADHD) is one of the most common childhood disorders and can continue.
AD/HD General Medical Information Mary Margaret Dagen, M.D. Mary Margaret Dagen, M.D. Westshore Family Medicine Westshore Family Medicine April 24, 2013.
CNS STIMULANTS SAMUEL AGUAZIM. What is the definition of a CNS stimulant? A CNS stimulant is a drug that increases motor activity, causes excitement and.
ADHD and initiation of drinking and drinking to intoxication in girls: Is there an association? Valerie S. Knopik, Pamela A.F. Madden, and Andrew C. Heath.
Helping inattentive, hyperactive and impulsive children Christine Merrell.
Review Session Thursday December 15 th at 3:00pm TH 173.
Students with Attention Deficit Disorders. Students with ADHD may be serviced under IDEA Under “other health impairment” having limited strength, vitality.
Understanding Students With Attention-Deficit/Hyperactivity Disorder
Drugs for the treatment of Attention-Deficit Hyperactivity Disorder
Attention Deficit Disorder in Children
Attention Deficit/Hyperactivity Disorder (ADD/ADHD) Kiefer, MaryJane ED 6362 – Education of Exceptional Children Dr. M. McCloulskey Fall 2001.
ADHD- Attention Deficit Hyperactivity Disorder
By: Heather Willis.  Inattention -- A child with ADHD:  Is easily distracted  Does not follow directions or finish tasks  Does not appear to be listening.
ADHD Abnormal Psychology 9a12f f6e86c576a030cc42d e_video.wmvhttp:// 9a12f f6e86c576a030cc42d.
BY MICHAEL PELSTER AND SARAH LEGGETT Attention-Deficit Hyperactivity Disorder (ADHD)
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 36 Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder.
The ADHD Toolkit ADHD information for parents 1. What is ADHD? A medical disorder diagnosed by a clinician (paediatrician or child psychiatrist) Three.
ATTENTION DEFICIT HYPERACTIVITY DISORDER IN INSTITUTIONALIZED CHILDREN University of Medicine and Pharmacy Tg. Mures Pharmacy Author: Paul Barac-Poponut.
ADHD Naturopathic Doctors Ontario
ADHD in the Home: Interventions and Strategies Dr. Charles Pemberton, Ed.D, LPCC.
And Alzheimer’s Disease
ADHD What is it and how do you know?. DSM-IV Where does this come in? What it says The menu approach: A. –Either (1) or (2)
Understanding and Helping Students with ADHD
ADHD and Psychopharmacology By Monica Robles M.D.
CONTINUITY CLINIC ADHD Evaluation. CONTINUITY CLINIC "Think of an absentminded professor who can find a cure for cancer but not his glasses in the mess.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 25 Central Nervous System Stimulants.
Soaud Dupree EEC 4731 Milestone 1.  ADHD- “a syndrome of attention and behavior disturbances that may improve when stimulant-type drugs are administered.”
Attention Deficit Hyperactivity Disorder Class Notes EDFN 645 October 22, 2008.
1700 UPS Dr. Suite 107 Louisville, KY Phone: Fax: com PEMBERTON.
Supplemental Info for Cases.  5-HT2A and D2 antagonist  Also antagonist of the D1, D4, α1, 5-HT1A, muscarinic M1 through M5, and H1 receptors.
DIFFERENTIATION: ATTENTION DEFICIT/HYPERACTIVITY DISORDER.
WEEK 13 ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Lyn Billington June 2006 Treatment of Attention Deficit/Hyperactivity Disorder Lyn Billington Deputy Pharmacy Manager Latrobe Regional Hospital.
1 Copyright © 2012, 2009, 2006, 2003 by Saunders, an imprint of Elsevier Inc. Chapter 20 CENTRAL NERVOUS SYSTEM STIMULANTS.
Drew Yanke M.A. TLLP …A medical condition characterized by inattention and/or hyperactivity-impulsivity One of the most common.
Attention Deficit Disorder Milena Teen Health 8 Definition:   A disorder that may include 9 specific symptoms of inattention and 9 symptoms of hyperactivity/impulsivity.
ADHD MEDICATIONS Myths and Facts ADHD Awareness Day, Oct 2011 by Theresa Cerulli, M.D. Neuropsychiatrist.
Dr TG Magagula 13 August Behavioral disorder: noise-making, motor driven.
Amphetamine Michelle Lubrano Teaching Concepts of Health Education I Drug Investigation Assignment Spring 2010.
Overdiagnosis and Overprescribing ADHD Diagnosed and treated with medication Diagnosed, but should seek other alternatives ADHD does not actually exist.
Attention-Deficit / Hyperactivity Disorder (ADHD) Trouble du déficit de l’attention/hyperactivité (TDAH) Claude Jolicoeur. m.d.
 An attention-deficit disorder is a developmental disorder characterized by developmentally inappropriate degrees of inattention, overactivity, and impulsivity.
Understanding Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADHD). Definition Attention deficit hyperactivity disorder; a disorder characterized by a persistent pattern.
Pharmacological Manipulation of the Nervous System Treatment vs. Enhancement By: David Hall 9/27/2007.
Chapter – 27 ATTENTION DEFICIT HYPERACTIVITY DISORDER.
Copyright © Allyn & Bacon 2008 Chapter 6: Students with Attention Deficit-Hyperactivity Disorder Chapter 6 Copyright © Allyn & Bacon 2008.
Chapter 29 Central Nervous System Stimulants Used to Treat Attention Deficit Hyperactivity Disorder and Agents Used to Treat Alzheimer’s Disease.
ADD or ADHD?  “Official” clinical diagnosis is Attention Deficit Hyperactivity Disorder, or ADHD  ADD used as generic term for all typ0es of ADHD  Basically.
注意力不足過動症 Attention-deficit/hyperactivity disorder.
Attention Deficit- Hyperactivity Disorder... A Closer Look Presented by Belinda Ingram, School Counselor West Bainbridge Elementary School.
By Anthony Anguiano Period 3
ADHD.
By Ashok Shanishetti.
Improving Diagnosis and Management of ADHD
Attention-Deficit/Hyperactivity Disorder
ADHD in adults Flavio Guzmán, MD.
CNS Stimulants Defination
CNS Stimulants: Uses (p. 210)
A ttention D eficit H yperactivity D isorder By: Bo Zhong.
Presentation transcript:

Psychopharmacological interventions for ADHD Dr. Charles Pemberton, Ed.D, LPCC Manbeena Sekhon, Doctoral Student

Today’s plan Not a complete presentation. Talk to your MD Why Study? ADHD Basic Elements of:  Methylphenidate  Dextroamphetamine  Atomoxetene When to use which.

Why Should Non-prescribers know this? Education Weekly monitoring Side-effect intervention Diagnosing Timing Reputation, future referrals

Attention Deficit Hyperactivity Disorder Within the “Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence” grouping, then subgrouped by the category of “disruptive or self injurious behavior”

ADHD, Major Diagnostic Features Often will not complete tasks Easily distracted by minor stimuli Work often messy and completed w/o thought Forgetful in day-to-day activities Impulsive (interrupting others, cannot wait turn, etc.) Fidgetiness Excessive talking

Prevalence of ADHD Estimated at 3-7% of school age children More common in males than females Often diagnosed during elementary school years.

Subtypes of ADHD ADHD, Combined Type  Criteria A1 & A2 both met for past 6 months ADHD, Inattentive Type  Criteria A1 met, but not A ADHD, Hyperactive-Impulsive Type  Criteria A2 met, but not A ADHD NOS  Prominent symptoms but do not meet diagnostic criteria

Diagnostic Criteria for ADHD A 1. Must exhibit 6 or more symptoms of inattention, persisting for minimum of 6 months: from list of 9 items, a through i.  fails to give close attention to details  often has difficulty sustaining attention  often does not seem to listen when spoken to directly  often has difficulty organizing tasks and activities  often loses things necessary for tasks  often easily distracted by extraneous stimuli  often forgetful in daily activities

Diagnostic Criteria, cont’d: A 2. Must exhibit 6 or more symptoms of hyperactivity-impulsivity, persisting for minimum of 6 months, from list of 9 items, a through i.  often fidgets with hands or feet or squirms in seat  often leaves seat in classroom  often runs about or climbs excessively  is often "on the go" or often acts as if "driven by a motor“  often talks excessively  often blurts out answers  often has difficulty awaiting turn  often interrupts or intrudes on others

Diagnostic Criteria, cont’d: B. symptom onset PRIOR to age 7 years C. impairment present in two or more environments D. clear clinically significant impairment in functioning E. cannot be accounted for by other mental disorder

Basic Elements of Methylphenidate Known as: Ritalin, Ritalin SR, Ritalin LA, Concerta, Metadate ER, Metadate CD, Focalin Pharmacology: It is a CNS stimulant, which is chemically related to amphetamine Preparations – 5, 10, 20 mg tabs; sustained release 20 mg tabs; LA 20, 30, and 40 mg capsules. The SR tablet should be swallowed and not crushed or chewed. Concerta comes in 18 and 36 mg extended release tablets. Metadate CD 20 mg capsules; Metadate ER 10 – and 20 – mg tabs. Focalin 2.5, - 5-, 10 - mg tabs.

Methylphenidate, cont’d Half-Life – 3-4 hours; 6-8 hours for sustained release It’s a schedule II controlled substance, requiring a triplicate prescription Pre-Drug Work-Up  Blood pressure and general cardiac status  baseline and periodic blood counts and liver function tests  Weight and growth should be monitored in children

Methylphenidate, cont’d Adverse Drug Reactions  Nervousness and insomnia; can be reduced by decreasing dose.  Cardiovascular – Hypertension, tachycardia, and arrhythmias.  CNS – Dizziness, euphoria, tremor, headache, precipitation of tics and Tourette’s syndrome, and rarely psychosis.  GI – Decreased appetite, weight loss.  Case reports of elevated liver enzymes and liver failure.  Hematological –Leukopenia and anemia have been reported  Growth Inhibition

Basic Elements of Dextroamphetamine Known as: Adderall, Adderall XR Pharmacology:causes the release of norepinepherine from neurons. At higher doses, it will also cause dopamine and serotonin release Preparations – Adderall 5-, 7.5-, 10-, 12.5-, 15-, 20-, 30-mg tablets; Adderall XR 5-, 10-, 15-, 20-, 25-, 30-mg capsules.

Dextroamphetamine, cont’d Half-Life – hours It’s a schedule II controlled substance, requiring a triplicate prescription Pre-Drug Work-Up  Blood pressure and general cardiac status should be evaluated prior to initiating dextroamphetamine.  Can precipitate tics  Contraindicated in in patients with hypertension, hyperthyroidism, cardiac disease or glaucoma. It is not recommended for psychotic patients ot patients with a history of substance abuse.  Weight and growth should be monitored in all children.

Dextroamphetamine, cont’d Adverse Drug Reactions  Side effects – most common side effects are psychomotor agitation, insomnia, loss of appetite, and dry mouth. Tolerance to loss of appetite tends to develop. Effect on sleep can be reduced by making sure no drug is given after 12 pm.  Cardiovascular – Palpitations, tachycardia, increased blood pressure.  CNS – Dizziness, euphoria, tremor, precipitation of tics, Tourette’s syndrome, and rarely, psychosis.  GI – Anorexia and weight loss, diarrhea, constipation.  Growth inhibition

Basic Elements of Atomoxetene Known as: Strattera Pharmacology:works via presynaptic norepinepherine transporter inhibition Preparations – 10, 18, 25, 40, and 60 mg capsules.

Atomoxetene, cont’d Half-Life – approximately 4 hours Not a schedule II controlled substance Clinical Guidelines –  Dividing the dose may reduce some side effects  Dose reductions are necessary in presence of moderate hepatic insufficiency  Atomoxetine should not be used within 2 weeks of discontinuation of a MAO inhibitor.  Atomoxetine should be avoided inpatients with narrow angle glaucoma and, it should be used with caution in patients with tachycardia, hypertension, or cardiovascular disease.  It can be discontinued without taper.  Pregnancy C category.

Atomoxetene, cont’d Adverse Drug Reactions  Cardiovascular – increased blood pressure and heart rate (similar to those seen with conventional psychostimulant).  BI – Anorexia, weight loss, nausea, abdominal pain.  Miscellaneous – Fatigue, dry mouth, constipation, urinary hesitancy and erectile dysfunction.

When to use, when to change Side effects Past history Substance abuse Efficacy Onset time Stimulant first line, Strattera second Follow MD

Closing Thoughts Stimulants still first line defense Look at choice of drug based upon time of release Be aware of study sponsor Addictive nature Subscribe to Medscape